Lycia Therapeutics prices $317.5M IPO
Lycia Therapeutics prices 17.64 million shares at $18, producing $317.52 million in gross proceeds.
What happened
Lycia Therapeutics priced an upsized initial public offering of 17.64 million shares at $18 each, producing $317.52 million in gross proceeds. The clinical-stage company estimated net proceeds of approximately $290.7 million after underwriting discounts, commissions and expenses.
Why it matters
Lycia is developing treatments designed to remove disease-causing proteins outside cells, initially targeting allergic and autoimmune conditions. The financing gives the company substantial capital to advance several clinical and research programmes while public investors assume the development risk.
The bigger picture
Biotechnology companies have faced a difficult listing market, so the offering may provide a signal about investor appetite for clinical-stage platforms. The figures should remain precise: $317.52 million is gross offering value, expected net proceeds are about $290.7 million, and trading began on 23 October.